DAVID A. PEURA, M.D.; LAWRENCE F. JOHNSON, M.D.
The opinions or assertions contained herein are those of the authors and are not to be construed as reflecting the views of the Department of the Army or the Department of Defense.
▸Requests for reprints should be addressed to Lawrence F. Johnson, M.D.; Gastroenterology Service, Walter Reed Army Medical Center; Washington, DC 20307-50001.
PEURA DA, JOHNSON LF. Cimetidine for Prevention and Treatment of Gastroduodenal Mucosal Lesions in Patients in an Intensive Care Unit. Ann Intern Med. 1985;103:173-177. doi: 10.7326/0003-4819-103-2-173
Download citation file:
Published: Ann Intern Med. 1985;103(2):173-177.
The efficacy of Cimetidine in the prevention and treatment of stress-induced gastroduodenal lesions was evaluated in a randomized, double-blind, placebo-controlled study in which serial endoscopy was used to examine patients without clinical evidence of bleeding who were admitted to a medical intensive care unit. Endoscopy showed that 14 of 21 patients treated with Cimetidine, compared with 5 of 18 patients treated with placebo, had normal or improved gastroduodenal mucosa (p < 0.05). Endoscopic signs of bleeding cleared or did not develop in 20 patients treated with Cimetidine and in 11 patients treated with placebo (p < 0.01). Significantly fewer blood transfusions were given to patients with endoscopic signs of bleeding in the cimetidine-treated group (0.5 ±0.3 [SE] units) than in placebo-treated patients (4.5 ±1.5 units; p < 0.05). The mortality rate was not statistically different between treatment groups. By preventing established gastroduodenal stress lesions from progressing in severity, Cimetidine diminished both bleeding and the need for transfusions.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only